For research use only. Not for therapeutic Use.
FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia[1].
FLT3-IN-4 (Compound 9u) shows potent inhibitory activities against MV4-11 and Molm-13 cells with IC50 values are 0.089±0.001 nM and 0.022±0.003 nM, respectively[1].
Catalog Number | I018997 |
CAS Number | 2304799-09-3 |
Synonyms | 1-[4-(4-amino-7-prop-2-enylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea |
Molecular Formula | C23H25N7O2 |
Purity | ≥95% |
InChI | InChI=1S/C23H25N7O2/c1-5-10-30-12-16(19-20(24)25-13-26-21(19)30)14-6-8-15(9-7-14)27-22(31)28-18-11-17(32-29-18)23(2,3)4/h5-9,11-13H,1,10H2,2-4H3,(H2,24,25,26)(H2,27,28,29,31) |
InChIKey | XIMGYPHSYIMHAW-UHFFFAOYSA-N |
SMILES | CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN(C4=NC=NC(=C34)N)CC=C |
Reference | [1]. Yuan X, et al. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia. J Med Chem. 2019 Apr 25;62(8):4158-4173. |